Compare Royal Caribbean Cruises Ltd (RCL) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Tenet Healthcare Corporation — how do they compare? Royal Caribbean Cruises Ltd trades at $283.29 (market cap $75.51B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 3.6× Tenet Healthcare Corporation's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Tenet Healthcare Corporation for 15 Days on average.
| RCL | THC | |
|---|---|---|
Market Cap | $75.51B | $20.92B |
Volume | 2,408,997 | 455,764 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $280.77 |
52-Week Low | $230.30 | $161.37 |
Typical Hold Time | 85 Days | 15 Days |
Enterprise Value | $98.15B | $32.00B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, down 2.58% on the day, amid mixed technical signals with bullish moving averages but overbought RSI levels. Fundamentally, the company shows strong recovery with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income reaching $4.3B. Recent developments include a $3 billion investment in Sandals Resorts and positive analyst sentiment with 51% buy ratings.
The outlook remains positive with analyst consensus target of $346.67 suggesting 23% upside potential. Key opportunities include expanding resort operations and strong booking trends, while risks involve high debt levels, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock presents a growth opportunity with manageable risks for long-term investors.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
